Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.55 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.55 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11902180 | 0.90 | PIK3CD (0.56) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL2507140 | 0.89 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL2508294 | 0.89 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL2502928 | 0.89 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL11900813 | 0.86 | PIK3CD (0.43) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL11902213 | 0.83 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL11900707 | 0.82 | PIK3CD (0.80) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL11901142 | 0.80 | PIK3CG (0.49) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677876 | 0.80 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16677822 | 0.80 | PIK3CD (0.61) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | claimed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | claimed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CD 2/4885PIK3CG 10/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.